Google
Trusted Resources: News & Events
Latest announcements and gatherings
New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Crisis
SANGUINATE™, the only investigational biopharmaceutical product currently in clinical development for the treatment of multiple comorbidities of sickle cell disease (SCD), is effective in returning red blood cells to a more normal morphology (shape) in patients experiencing vaso-occlusive crisis (VOC) related to SCD, according to research presented at the 11th Annual Symposium of the Foundation for Sickle Cell Disease Research (FSCDR) in Fort Lauderdale, Fla.
+myBinderRelated Content
-
Gut Microbiome Translates Stress Into Sickle Cell CrisesA new study shows how chronic psychologi...
-
What Is a Sickle Cell Crisis?At some point in your life, you’ll acc...
-
Pioneering a New Therapy for Sickle Cell DiseaseThe science behind sickle cell disease (...
-
Opioid use is not associated with in-hospital mortality among patients with sickle cell disease in the United StatesBackground: Vaso-occlusive pain crises ...
-
Conversation With Women in the Sickle Cell CommunitySickle Cell Project of NW Ohio at Neighb...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
Stem cell gene-editing method may be breakthrough for sickle cell researchResearchers have cured mice with a genet...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.